消化系统肿瘤新标志抗survivin抗体的临床应用_医学论文.docVIP

消化系统肿瘤新标志抗survivin抗体的临床应用_医学论文 消化系统肿瘤新标志抗survivin抗体的临床应用_医学论文 作者：王小平，秦力维，郭建巍，马骢，杨霄鹏，吕同德，高福兴，刘敏 【摘要】 　　目的: 建立生存素(survivin)抗体的检测方法，并进行临床标本检测. 方法: 用镍离子亲和层析纯化的survivin融合蛋白包被酶标板，建立基于重组融合蛋白的抗survivin抗体检测方法，并对434份血清标本进行检测， 其中包括204例消化系统肿瘤, 186例癌前病变和44例正常对照. 结果: 在204例消化系统肿瘤中， 甲胎蛋白(AFP)和癌胚抗原(CEA)的阳性率分别为14.2%和16.7%，抗survivin抗体阳性率为30.9%， 本方法的特异度为93.6% 在肠癌中CEA阳性率为11.1%（6/54）, 抗survivin抗体阳性率为44.4%（24/54, 0.05)；在胃癌中CEA阳性率为20%, 抗survivin抗体阳性率为33.3% (Pgt0.05)；在食管癌中, 抗survivin抗体阳性率高达40%, CEA阳性率仅为6.7% (0.05). 在186例癌前病变中, 抗survivin抗体阳性率31.7%, AFP和CEA阳性率分别为10.8%和16.7%；在消化性溃疡患者中, 抗survivin抗体和CEA阳性率均为33.3%；在直肠息肉中抗survivin抗体阳性率33.3%，CEA的阳性率仅为5.6% (0.05)；在慢性结肠炎患者, 抗survivin抗体阳性率40%，CEA阳性率20% (0.05). 结论: 建立的抗survivin抗体检测方法和对消化系统肿瘤抗survivin抗体检测的基础资料，可为抗survivin抗体作为消化系统肿瘤新标志分子研究奠定基础. 【关键词】 存活素；融合蛋白；肿瘤标志；间接ELISA法；消化系统肿瘤 　　【Abstract】 AIM: To establish an indirect ELISAbased method for detecting the antisurvivin antibody in sera of patients with digestive carcinomas and to discuss its clinical value. METHODS: An indirect ELISA was established by coating recombinant survivin protein purified with NiNTA agarose affinity chromatography. Then 434 serum samples from digestive cancer patients (n=204), precancerous lesion patients (n=186) and normal subjects (n=44) were detected and analyzed. RESULTS: The positive rates of alpha fetoprotein (AFP), carcinoembryonic antigen (CEA) and antisurvivin antibody in the sera of 204 patients of digestive carcinomas were 14.2%, 16.7% and 30.9%, respectively. The specificity of this method was 93.6%. CEA and the elevated antisurvivin antibody were detected in 11.1% (6/54) and 44.4% of intestinal carcinoma specimens (24/54, 0.05). The positive rates of CEA and antisurvivin antibody in gastric carcinoma specimens were 20% and 33.3% (Pgt0.05). Antisurvivin positive patients were 6 of 15 (40%) and CEA positive patients were 1 of 15 (6.7%, 0.05) in esophageal carcinoma. The positive rates of AFP, CEA and antisurvivin antibody in 186 patients with precancerous